June 08, 2015 8:00am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK )
and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint
conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015,
to discuss the previously announced entry into a merger agreement for
OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference
Laboratories’ second quarter financial results. This joint call will be
in lieu of the separate earnings call previously announced by
Bio-Reference Laboratories.
This Smart News Release features multimedia. View the full release here:
The conference call will be available via phone and webcast. The
conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required. A link to the live
webcast is also included below.
WHEN: Thursday, June 11, 2015, 8:30 a.m. ET
DOMESTIC & CANADA DIAL-IN: 1-877-407-0789
INTERNATIONAL DIAL-IN: 1-201-689-8562
LIVE WEBCAST LINK: http://public.viavid.com/index.php?id=114915
For those unable to participate in the conference call or webcast, a
replay will be available beginning June 11, 2015 at 5 p.m. ET for a
period of time. To access the replay, dial 1-877-870-5176 or
1-858-384-5517. The replay passcode is 13611685.
The replay can also be accessed for a period of time on OPKO’s website
at www.opko.com .
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies.
About Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories, Inc. is one of the largest and fastest
growing full service diagnostic laboratories in the world, providing
clinical testing services to physician offices, clinics, hospitals,
long- term care facilities and employers while also advancing drug
discovery and development with disease foundations, academic and
pharmaceutical partners. Bio-Reference Laboratories’ comprehensive
testing capabilities and expertise spans molecular diagnostics,
anatomical pathology, women's health, oncology and rare disease
genetics. Bio-Reference Laboratories, and its subsidiaries, has an
international presence in more than 50 countries. For more information,
visit www.bioreference.com .
Important Information For Investors And Shareholders
This communication does not constitute an offer to buy or sell or the
solicitation of an offer to buy or sell any securities or a solicitation
of any vote or approval. This communication relates to a proposed
business combination between Bio-Reference Laboratories, Inc.
(“Bio-Reference Laboratories”) and OPKO Health, Inc. (“OPKO”). In
connection with this proposed business combination, Bio-Reference
Laboratories and/or OPKO will file relevant materials with the
Securities Exchange Commission (the “SEC”), including an OPKO
registration statement on Form S-4 that will include a proxy statement
of Bio-Reference Laboratories and constitute a prospectus of OPKO.
INVESTORS AND SECURITY HOLDERS OF BIO-REFERENCE LABORATORIES AND OPKO
ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS
THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND
WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Any definitive proxy statement (if and when available) will
be mailed to shareholders of Bio-Reference Laboratories. Investors and
security holders will be able to obtain free copies of these documents
(if and when available) and other documents filed with the SEC by
Bio-Reference Laboratories and/or OPKO through the website maintained by
the SEC at www.sec.gov .
Copies of the documents filed with the SEC by Bio-Reference Laboratories
will be available free of charge on Bio-Reference Laboratories’ website
at http://www.bioreference.com
or by contacting Bio-Reference Laboratories’ Investor Relations
Department by email at tmackay@bioreference.com
or by phone at (201) 791-2600. Copies of the documents filed with the
SEC by OPKO will be available free of charge on OPKO’s website at www.opko.com
or by contacting OPKO’s Investor Relations Department by email at contact@opko.com
or by phone at (305) 575-4100.
Participants in Solicitation
Bio-Reference Laboratories, OPKO, their respective directors and certain
of their respective executive officers may be considered participants in
the solicitation of proxies in connection with the proposed transaction.
Information about the directors and executive officers of Bio-Reference
Laboratories is set forth in its Annual Report on Form 10-K for the year
ended October 31, 2014, which was filed with the SEC on January 13,
2015, its Quarterly Report on Form 10-Q for the quarter ended January
31, 2015 which was filed with the SEC on March 9, 2015 and its Current
Reports on Form 8-K, which were filed with the SEC on March 5, 2015, and
April 29, 2015. Information about the directors and executive officers
of OPKO is set forth in its amended Annual Report on Form 10-K for the
year ended December 31, 2014, which was filed with the SEC on February
27, 2015 and April 30, 2015, its proxy statement for its 2015 annual
meeting of stockholders, which was filed with the SEC on May 7, 2015,
its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015
which was filed with the SEC on May 11, 2015 and its Current Report on
Form 8-K, which was filed with the SEC on March 19, 2015.
These documents can be obtained free of charge from the sources
indicated above. Additional information regarding the participants in
the proxy solicitations and a description of their direct and indirect
interests, by security holdings or otherwise, will be contained in the
proxy statement/prospectus and other relevant materials to be filed with
the SEC when they become available.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this communication regarding the proposed
acquisition of Bio-Reference Laboratories by OPKO, including any
statements regarding the expected timetable for completing the proposed
transaction, synergies, benefits and opportunities of the proposed
transaction, future opportunities for the combined company and products,
future financial performance and any other statements regarding OPKO’s
and Bio-Reference Laboratories’ future expectations, beliefs, plans,
objectives, financial conditions, assumptions or future events or
performance that are not historical facts are “forward-looking”
statements made within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect,”
“if,” “intend,” “estimate,” “probable,” “project,” “forecasts,”
“predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,”
“potential,” “may,” “might,” “anticipate,” “likely” “plan,”
“positioned,” “strategy,” and similar expressions, and the negative
thereof, are intended to identify forward-looking statements.
All forward-looking information are subject to numerous risks and
uncertainties, many of which are beyond the control of Bio-Reference
Laboratories and OPKO, that could cause actual results to differ
materially from the results expressed or implied by the statements.
These risks and uncertainties include, but are not limited to: failure
to obtain the required vote of Bio-Reference Laboratories’ shareholders;
the timing to consummate the proposed transaction; the risk that a
condition to closing of the proposed transaction may not be satisfied or
that the closing of the proposed transaction might otherwise not occur;
the risk that a regulatory approval that may be required for the
proposed transaction is not obtained or is obtained subject to
conditions that are not anticipated; the diversion of management time on
transaction-related issues; ability to successfully integrate the
businesses; risk that the transaction and its announcement could have an
adverse effect on Bio-Reference Laboratories’ ability to retain
customers and retain and hire key personnel; the risk that any potential
synergies from the transaction may not be fully realized or may take
longer to realize than expected; new information arising out of clinical
trial results; and the risk that the safety and/or efficacy results of
existing clinical trials will not support continued clinical
development, as well as risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments. In addition, forward-looking
statements may also be adversely affected by general market factors,
competitive product development, product availability, federal and state
regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this communication may become outdated over time. OPKO and
Bio-Reference Laboratories do not assume any responsibility for updating
any forward-looking statements. Additional information concerning these
and other factors can be found in Bio-Reference Laboratories’ and OPKO’s
respective filings with the SEC and available through the SEC’s
Electronic Data Gathering and Analysis Retrieval system at www.sec.gov ,
including Bio-Reference Laboratories’ and OPKO’s most recent Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. The foregoing list of important factors is not exclusive.
Bio-Reference Laboratories and OPKO assume no obligation to update or
revise any forward-looking statements as a result of new information,
future events or otherwise, except as may be required by law. Readers
are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150608005669/en/
Steve Rubin or Adam Logal
or
BRLI
Source: OPKO Health, Inc.
Released June 8, 2015
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page